000095801 001__ 95801
000095801 005__ 20230921135435.0
000095801 0247_ $$2doi$$a10.3390/vaccines8030459
000095801 0248_ $$2sideral$$a120239
000095801 037__ $$aART-2020-120239
000095801 041__ $$aeng
000095801 100__ $$aRoy, S.
000095801 245__ $$aImpact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity
000095801 260__ $$c2020
000095801 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095801 5203_ $$aThe efficacy of the intranasally (i.n.) delivered live attenuated influenza vaccine (LAIV) is variable and, in some seasons, suboptimal. In this study, we report that LAIV exhibits cross-protective efficacy in mice, potentially associated with cellular immunity as opposed to antigen-specific antibody responses. However, pre-exposure to the intramuscularly (i.m.) delivered inactivated influenza vaccine (IIV) severely impaired LAIV-induced cross-protection against heterologous challenge, potentially by inhibiting replication of LAIV. Our findings suggest that pre-existing immunity afforded by IIV suppresses cross-protective T cell immunogenicity of LAIV.
000095801 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095801 590__ $$a4.422$$b2020
000095801 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b63 / 140 = 0.45$$c2020$$dQ2$$eT2
000095801 591__ $$aIMMUNOLOGY$$b74 / 162 = 0.457$$c2020$$dQ2$$eT2
000095801 592__ $$a1.296$$b2020
000095801 593__ $$aDrug Discovery$$c2020$$dQ1
000095801 593__ $$aImmunology$$c2020$$dQ1
000095801 593__ $$aPharmacology (medical)$$c2020$$dQ1
000095801 593__ $$aPharmacology$$c2020$$dQ1
000095801 593__ $$aInfectious Diseases$$c2020$$dQ1
000095801 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095801 700__ $$aWilliams, C.M.
000095801 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J.$$uUniversidad de Zaragoza
000095801 700__ $$aWijesundara, D.K.
000095801 700__ $$aFuruya, Y.
000095801 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000095801 773__ $$g8, 3 (2020), 459 [1-6 pp.]$$tVaccines$$x2076-393X
000095801 8564_ $$s466242$$uhttps://zaguan.unizar.es/record/95801/files/texto_completo.pdf$$yVersión publicada
000095801 8564_ $$s503025$$uhttps://zaguan.unizar.es/record/95801/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095801 909CO $$ooai:zaguan.unizar.es:95801$$particulos$$pdriver
000095801 951__ $$a2023-09-21-13:30:58
000095801 980__ $$aARTICLE